Lysosomes and Fas-mediated Liver Cell Death
Overview
Authors
Affiliations
A number of studies, mostly performed ex vivo, suggest that lysosomes are involved in apoptosis as a result of a release of their cathepsins into the cytosol. These enzymes could then contribute to the permeabilization of the outer mitochondrial membrane; they could also activate effector caspases. The present study aims at testing whether the membrane of liver lysosomes is disrupted during Fas-mediated cell death of hepatocytes in vivo, a process implicated in several liver pathologies. Apoptosis was induced by injecting mice with aFas (anti-Fas antibody). The state of lysosomes was assessed by determining the proportion of lysosomal enzymes (beta-galactosidase, beta-glucuronidase, cathepsin C and cathepsin B) present in homogenate supernatants, devoid of intact lysosomes, and by analysing the behaviour in differential and isopycnic centrifugation of beta-galactosidase. Apoptosis was monitored by measuring caspase 3 activity (DEVDase) and the release of sulfite cytochrome c reductase, an enzyme located in the mitochondrial intermembrane space. Results show that an injection of 10 microg of aFas causes a rapid and large increase in DEVDase activity and in unsedimentable sulfite cytochrome c reductase. This modifies neither the proportion of unsedimentable lysosomal enzyme in the homogenates nor the behaviour of lysosomes in centrifugation. Experiments performed with a lower dose of aFas (5 microg) indicate that unsedimentable lysosomal hydrolase activity increases in the homogenate after injection but with a marked delay with respect to the increase in DEVDase activity and in unsedimentable sulfite cytochrome c reductase. Comparative experiments ex vivo performed with Jurkat cells show an increase in unsedimentable lysosomal hydrolases, but much later than caspase 3 activation, and a release of dipeptidyl peptidase III and DEVDase into culture medium. It is proposed that the weakening of lysosomes observed after aFas treatment in vivo and ex vivo results from a necrotic process that takes place late after initiation of apoptosis.
Buckel M, Maclean P, Knight J, Lawler P, Proudfoot A Crit Care. 2023; 27(1):460.
PMID: 38012789 PMC: 10683227. DOI: 10.1186/s13054-023-04752-8.
Innelli P, Lopizzo T, Paterno G, Bruno N, Radice R, Bertini P Diagnostics (Basel). 2023; 13(7).
PMID: 37046568 PMC: 10093224. DOI: 10.3390/diagnostics13071350.
DPP3: From biomarker to therapeutic target of cardiovascular diseases.
Ye P, Duan W, Leng Y, Wang Y, Tan X, Wang W Front Cardiovasc Med. 2022; 9:974035.
PMID: 36312232 PMC: 9605584. DOI: 10.3389/fcvm.2022.974035.
The role of lysosome in cell death regulation.
Yu F, Chen Z, Wang B, Jin Z, Hou Y, Ma S Tumour Biol. 2015; 37(2):1427-36.
PMID: 26631036 DOI: 10.1007/s13277-015-4516-6.
Protease signalling: the cutting edge.
Turk B, Turk D, Turk V EMBO J. 2012; 31(7):1630-43.
PMID: 22367392 PMC: 3321211. DOI: 10.1038/emboj.2012.42.